Merck & Co. Inc. (MRK) Q1 2026 (USD): Adj. EPS -1.28 (exp. -1.47), Revenue 16.29bln (exp. 15.85bln), Keytruda sales 8bln (exp. 7.62bln)

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Iranian Supreme Leader says a new chapter for the Gulf and Strait of Hormuz is taking shape, via X

Royal Caribbean Group (RCL) Q1 2026 (USD): Adj. EPS 3.48 (exp. 3.22), Revenue 4.45bln (exp. 4.46bln)

Merck & Co. Inc. (MRK) Q1 2026 (USD): Adj. EPS -1.28 (exp. -1.47), Revenue 16.29bln (exp. 15.85bln), Keytruda sales 8bln (exp. 7.62bln)

Caterpillar Inc. (CAT) Q1 2026 (USD): Adj. EPS 5.54 (exp. 4.65), Revenue 17.4bln (exp. 16.53bln)

US President Trump is reportedly considering significant new combat operations in Iran to resolve a deadlock, Semafor reports

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.
  • Q1 GAAP and non-GAAP loss per share include USD 3.62/shr charge for acquisition of Cidara.

Guidance

  • FY adj. EPS 5.04-5.16 (exp. 5.10).
  • FY sales 65.8-67bln (exp. 66.6bln).

Context

Merck & Co. reported Q1 results that beat expectations on both adjusted EPS and revenue, with particularly strong sales from Keytruda, which exceeded estimates significantly. This performance could signal robust demand in the pharmaceutical sector, potentially bolstering confidence in the stock’s outlook and influencing peers in the industry, despite the present GAAP losses due to an acquisition charge.

Related headlines

The feed had this first.

Use the Platform